GSK plc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 03:30PM GMT
James Daniel Gordon - JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning. I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, I've got the pleasure of introducing the GSK presentation. You're going to hear from GSK, CEO, Emma Walmsley, and we can have the Q&A after in this presentation room. So thanks a lot for joining us today. Emma looking forward to the presentation.

Emma Natasha Walmsley - GSK plc - CEO & Director

Thank you very much, James. Good morning, good afternoon to anyone that's watching a very happy new year to you all. And let me say, of course, how absolutely wonderful it is to be able to attend today's conference in person.

Please turn to our usual cautionary statement regarding forward-looking statements first, and then please turn to Slide 3. Today, I want to leave you with 4 key things. Firstly, GSK is now a focused global biopharma company with a unique strategy focused on the prevention and treatment of disease.

We are a world leader in infectious diseases with an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot